Latest Animal Health News

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Apiam Animal Health reported a challenging FY25 with underperformance in its core clinical segment but has rebounded strongly in Q1 FY26. The company is now poised for acquisition by Adamantem Capital, offering shareholders a premium cash and scrip deal.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Terragen Holdings has secured a major purchase order from Mort & Co Fertilisers for its Great Land Plus® bio-stimulant, projecting a significant sales boost in 2026. This deal underscores growing demand for sustainable agricultural solutions.

Elders Limited reported a robust FY25 with a 12% rise in underlying EBIT to $143.5 million and declared a fully franked final dividend of 18 cents per share. The agribusiness is optimistic about FY26, buoyed by strategic acquisitions and a new divisional model.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Apiam Animal Health Limited has entered a binding agreement with Adamantem Capital Fund II for a $228.4 million acquisition via a scheme of arrangement, offering shareholders a significant premium and flexible cash or scrip consideration options.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.